Pre-Made Topsalysin biosimilar, Fusion Protein: Recombinant therapeutic protein targeting proaerolysin fused with hexahistidine for drug discovery and mechanism of action (MOA) research

Pre-Made Topsalysin biosimilar, Fusion Protein: Recombinant therapeutic protein targeting proaerolysin fused with hexahistidine is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Topsalysin (PRX302), is a modified recombinant protein that has been engineered to be selectively activated by an enzyme in the prostate, leading to localized cell death and tissue disruption without damaging neighbouring tissue and nerves. Topsalysin binds to the glycosylphosphatidylinositol (GPI)- anchored receptors on the cell surface of prostate cells. Once activated by the prostate-specific antigen (PSA), topsalysin combines with other activated topsalysin molecules, forming stable transmembrane pores that induce cell death. The prostate specific activation of topsalysin by enzymatically active PSA thus limits exposure of non-prostate tissues to the drug’s activity, contributing to the safety of the therapy.

Topsalysin is a genetically modified form of proaerolysin in which the native furin activation site has been replaced with a sequence that is highly specific for enzymatically active prostate-specific antigen (PSA) for activation, present only in prostate tissue. After activation, Topsalysin spontaneously oligomerizes and forms a stable transmembrane heptameric pore that leads to cell death. Topsalysin  is used to treat the prostate cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1025-1mg	1mg	3090
GMP-Bios-INN-1025-10mg	10mg	Inquiry
GMP-Bios-INN-1025-100mg	100mg	Inquiry
GMP-Bios-INN-1025-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Topsalysin biosimilar, Fusion Protein: Recombinant therapeutic protein targeting proaerolysin fused with hexahistidine
INN Name	Topsalysin
Target	proaerolysin
Format	Fusion Protein
Derivation	Aeromonas hydrophila
Species Reactivity	human
CH1 Isotype	Fusion - proaerolysin (engineered with a PSA cutting site) - hexahistidine
VD LC	Fusion - proaerolysin (engineered with a PSA cutting site) - hexahistidine
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Sophiris Bio, Inc. (San Diego CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0